Hidradenitis suppurativa: clinical features, comorbidities and quality of life in Colombia
DOI:
https://doi.org/10.29176/2590843X.1759Keywords:
Hidradenitis suppurativa, Epidemiology, Quality of lifeAbstract
Introduction: Hidradenitis suppurativa is a chronic inflammatory skin disease that manifests in the form of painful and recurrent and suppurating lesions. In Colombia, there is little epidemiological information on this pathology. This study aims to describe the severity of symptoms, sociodemographic factors and quality of life of HS patients in Colombia.
Material and Methods: This is an exploratory, multicenter, observational, cross-sectional study conducted in 8 dermatology centers in Colombia.
Results: Several parameters were collected from 90 patients: 23.3% of the patients were classified as Hurley stage I, 42.2% as stage II, and 34.4% as stage III. Patients classified within Hurley's stage III severity had the highest mean BMI (30.2 kg/m2). The mean time elapsed from onset of symptoms to diagnosis was 64.6 months and the mean to the start of treatment from diagnosis was 1.7 months. Comorbidities were frequent, with obesity being the most common (38.9%). Regarding quality of life, a statistically significant difference was found in the DLQI from Hurley’s severity index (p-value=0.0056), in the utility index relative to the Hurley severity index (p-value=0.011) and in the EQ-5D-5L visual analog scale (EQ-5D-5L-VAS; p-value=0.001).
Conclusions: As in all other countries, in Colombia, patients with hidradenitis suppurativa require early and appropriate diagnosis and treatment. This study can be used to help physicians gain a better understanding of the disease, which could lead to better patient management.
Author Biographies
Hector Castellanos, Universidad Nacional de Colombia. Coordinador Académico Unidad de Dermatología
Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia.
Gloria A. Vargas, Universidad de Antioquia
Fundación San Vicente de Paul, Medellín, Colombia
Lili Rueda, Universidad El Bosque
MedPlus, Centro de Recuperación Integral, Bogotá, Colombia
Liliana Gonzalez, Caja de Compensación Familiar - CAFAM, Bogotá, Colombia
Caja de Compensación Familiar - CAFAM, Bogotá, Colombia
Esperanza Melendez, Centro Integral de Reumatología del Caribe - Circaribe, Barranquilla, Colombia
Centro Integral de Reumatología del Caribe - Circaribe, Barranquilla, Colombia
Maria I Arredondo, Hospital Pablo Tobón Uribe
Hospital Pablo Tobón Uribe, Medellín, Colombia
Janeth T Acosta, Abbvie, Bogotá, Colombia
Abbvie, Bogotá, Colombia
References
Saunte DML, Jemec GBE. Hidradenitis suppurativa: Advances in diagnosis and treatment. Vol. 318, JAMA - Journal of the American Medical Association. American Medical Association; 2017. p. 2019–32.
Matusiak Ł, Szczęch J, Kaaz K, Lelonek E, Szepietowski JC. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018 Feb;98(2):191–4.
Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Vol. 2, Dermato-Endocrinology. Dermatoendocrinol; 2010. p. 9–16.
Lee EY, Alhusayen R, Lansang P, Shear N, Yeung J. Qu’est-ce que l’hidradénite suppurée? Vol. 63, Canadian Family Physician. College of Family Physicians of Canada; 2017. p. 114.
Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. Vol. 62, Journal of the American Academy of Dermatology. Mosby Inc.; 2010.
Matusiak. Profound consequences of hidradenitis suppurativa: a review. Vol. 183, British Journal of Dermatology. Blackwell Publishing Ltd; 2020. p. e171–7.
Nguyen T V., Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. Vol. 35, Journal of the European Academy of Dermatology and Venereology. Blackwell Publishing Ltd; 2021. p. 50–61.
FINLAY AY, KHAN GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011 Dec;20(10):1727–36.
Von Der Werth JM, Jemec GBE. Morbidity in patients with hidradenitis suppurativa. Br J Dermatol. 2001;144(4):809–13.
Jemec GBE, Heidenheim M, Nielsen NH. Hidradenitis suppurativa - Characteristics and consequences. Clin Exp Dermatol. 1996;21(6):419–23.
Riis PT, Ring HC, Themstrup L, Jemec GB. The role of androgens and estrogens in hidradenitis suppurativa - a systematic review. Acta Dermatovenerologica Croat. 2016;24(4):239–49.
Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. Vol. 29, Journal of the European Academy of Dermatology and Venereology. Blackwell Publishing Ltd; 2015. p. 619–44.
Von Der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatology Venereol. 2000;14(5):389–92.
König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198(3):261–4.
West R. Tobacco smoking: Health impact, prevalence, correlates and interventions. Psychol Heal. 2017 Aug;32(8):1018–36.
Jorgensen AHR, Aarestrup J, Baker JL, Thomsen SF. Association of Birth Weight, Childhood Body Mass Index, and Height with Risk of Hidradenitis Suppurativa. JAMA Dermatology. 2020 Jul;156(7):746–53.
Theut Riis P, Saunte DM, Benhadou F, del Marmol V, Guillem P, El-Domyati M, et al. Low and high body mass index in hidradenitis suppurativa patients—different subtypes? J Eur Acad Dermatology Venereol. 2018 Feb;32(2):307–12.
Kokolakis G, Wolk K, Schneider-Burrus S, Kalus S, Barbus S, Gomis-Kleindienst S, et al. Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. Dermatology. 2020 Sep;236(5):421–30.
Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, et al. Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study. Ann Dermatol Venereol. 2018 May;145(5):331–8.
Jørgensen AHR, Holm JG, Ghazanfar MN, Yao Y, Ring HC, Thomsen SF. Factors affecting quality of life in patients with hidradenitis suppurativa. Arch Dermatol Res. 2020 Aug;312(6):427–36.
Versteegh MM, Leunis A, Uyl-De Groot CA, Stolk EA. Condition-specific preference-based measures: Benefit or burden? Value Heal. 2012 May;15(3):504–13.
Gergely LH, Gáspár K, Brodszky V, Kinyó, Szegedi A, Remenyik, et al. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. J Eur Acad Dermatology Venereol. 2020 Nov;34(11):2584–92.
Bató A, Brodszky V, Gergely LH, Gáspár K, Wikonkál N, Kinyó Á, et al. The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. Qual Life Res. 2021;30(5).
Kucinskiene V, Jariene V, Valiukeviciene S. Clinical characteristics of hidradenitis suppurativa patients from a reference centre in Kaunas, Lithuania. Dermatology. 2020 Feb;236(1):66–70.
Morteza Seyed Jafari S, Knüsel E, Cazzaniga S, Hunger RE. A Retrospective Cohort Study on Patients with Hidradenitis Suppurativa. Dermatology. 2018 Jul;234(1–2):71–8.
Katoulis AC, Liakou AI, Rotsiamis N, Bonovas S, Bozi E, Rallis E, et al. Descriptive Epidemiology of Hidradenitis Suppurativa in Greece: A Study of 152 Cases. Ski Appendage Disord. 2017 Oct;3(4):197–201.
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Hector Castellanos, Gloria A. Vargas, Lili Rueda, Liliana Gonzalez, Esperanza Melendez, Maria I Arredondo, Janeth T Acosta
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
